Showing 5081-5090 of 9747 results for "".
- Dr. Lain Discusses Predictive Modeling for PsO Biologic Selectionhttps://practicaldermatology.com/news/Dr-Lain-Discusses-Predictive-Modeling-PsO-Biologic-Selection/2471252/Edward (Ted) Lain, MD, MBA, reminded attendees at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, that a method exists for selecting the best class of biologic for each psoriasis patient. “I just want to keep this in the public conscience here,” Dr. Lain said. “There i
- EFFISAYIL 2 Data Suggest Unmet Needs in Generalized Pustular Psoriasis Carehttps://practicaldermatology.com/news/effisayil-2-data-suggest-unmet-needs-in-generalized-pustular-psoriasis-care/2471250/Baseline data from the EFFISAYIL 2 trial suggested that traditional small-molecule therapies fail to adequately address the burden of generalized pustular psoriasis (GPP). The analysis, presented as a poster at Masterclas
- New Option for Molluscum Expected Soonhttps://practicaldermatology.com/news/New-Option-Molluscum-Expected-Soon/2471226/Perhaps the most important measure a dermatologist can take after diagnosing a patient with molluscum is to reassure them that it is not a big deal, Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, said at Winter Clinical Hawaii 2025 in Waikoloa Village, Hawaii.
- Dr. Lebwohl: Don't Delay GPP Treatment for TB Testing or Skin Biopsyhttps://practicaldermatology.com/news/Dr-Lebwohl-Dont-Delay-GPP-Treatment-TB-Testing-Skin-Biopsy/2471222/Generalized pustular psoriasis (GPP) treatment should not be delayed while waiting for a tuberculosis screening, according to Mark Lebwohl, MD. Speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, Dr. Lebwohl recommended initiating spesolimab therapy immediately
- Dr. Siegel Discusses Sedation Without Drugshttps://practicaldermatology.com/news/Dr-Siegel-Discusses-Sedation-Without-Drugs/2471217/A significant portion of today’s patient population is interested in all-natural alternatives to drugs when possible, and sedation is an area where some useful options exist, according to Daniel M. Siegel, MD. “Sedation without drugs [is important] if you have new-age patients or, I guess,
- 'Dr. Pimple Popper' Offers Social Media Advicehttps://practicaldermatology.com/news/Dr-Pimple-Popper-Offers-Social-Media-Advice/2471209/Social media transformed Sandra Lee, MD, FAAD, FAACS, into “Dr. Pimple Popper.” While not every dermatologist aspires to have their own television show, many would like to maximize the impact of their social media presence, and Dr. Lee shared pearls from her own experience at the Winter Clinical
- Dr. Swanson: Dupilumab/Vaccines Question Has Been Answeredhttps://practicaldermatology.com/news/Dr-Swanson-Dupilumab-Vaccines-Question-Has-Been-Answered/2471166/The biggest remaining question about dupilumab has been answered by the allergy and immunology community, Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “The only realy question
- POETYK-PSO LTE: No New Safety Signals for Deucravacitinib at Five Yearshttps://practicaldermatology.com/news/poetyk-lte-no-new-safety-signals-for-deucravacitinib-at-five-years/2471170/Sotyktu (deucravacitinib) showed sustained efficacy and an acceptable safety profile over a period of 5 years in adults with moderate-to-severe plaque psoriasis, according to an announcement by Bristol Myers Squibb. Based on rec
- Acne Vaccine Could Be 'Revolutionary,' Dr. Stein Gold Sayshttps://practicaldermatology.com/news/Acne-Vaccine-Could-Be-Revolutionary-Dr-Stein-Gold-Says/2471165/The next major breakthrough in acne could be a “revolutionary” vaccine targeting the strain of c. Acnes bacteria that produces the Hyl-A enzyme, Linda Stein Gold, MD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “It is still in early clinical trials, but I t
- Nemolizumab Approved by European Commission for Moderate-to-severe Prurigo Nodularishttps://practicaldermatology.com/news/nemolizumab-approved-european-commission-for-moderate-to-severe-prurigo-nodularis/2471164/Nemolizumab has been approved by the European Commission for the treatment of moderate-to-severe prurigo nodularis, according to an announcement from Galderma. The approval of the monoclonal antibody (marketed as Nemluvio) fol